Insulet Co. (NASDAQ:PODD) Stock Holdings Lessened by Swiss National Bank

Swiss National Bank lessened its stake in Insulet Co. (NASDAQ:PODD) by 4.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 198,100 shares of the medical instruments supplier’s stock after selling 9,200 shares during the quarter. Swiss National Bank owned 0.28% of Insulet worth $51,718,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. acquired a new position in shares of Insulet in the fourth quarter worth $36,000. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Insulet by 30.1% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier’s stock valued at $2,192,000 after purchasing an additional 1,942 shares in the last quarter. Fisher Asset Management LLC increased its position in Insulet by 0.9% in the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock worth $81,719,000 after purchasing an additional 3,113 shares during the last quarter. Orion Portfolio Solutions LLC raised its stake in shares of Insulet by 86.2% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock worth $1,822,000 after purchasing an additional 3,623 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. lifted its holdings in shares of Insulet by 5.7% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock valued at $35,708,000 after buying an additional 8,301 shares during the last quarter.

Insulet Stock Up 4.4 %

NASDAQ PODD opened at $255.44 on Friday. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a market cap of $17.94 billion, a PE ratio of 44.12, a PEG ratio of 3.62 and a beta of 1.29. The firm has a 50-day simple moving average of $272.54 and a 200 day simple moving average of $254.96.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. On average, research analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on PODD shares. Royal Bank of Canada began coverage on Insulet in a report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price objective on the stock. Canaccord Genuity Group increased their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Citigroup lifted their price objective on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. increased their target price on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Finally, StockNews.com cut Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $292.06.

Insider Activity

In related news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.47% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.